Abstract
Lung cancer continues to be the leading cause of cancer-related deaths in the western civilization and developing countries. Non-small cell lung cancer (NSCLC) accounts for > 85% of all cases of lung cancer. Since most patients with NSCLC have advanced disease at diagnosis, to date chemotherapy with third-generation platinum-based doublets represents the standard of care. However, a plateau has been reached with the use of cytotoxic chemotherapy in advanced NSCLC. Advances in the knowledge of tumour biology and mechanisms of oncogenesis have granted the singling out of several molecular targets for NSCLC treatment. In particular, the epidermal growth factor receptor (EGFR), a member of the ErbB family and commonly overexpressed in NSCLC, is one of the most studied targets. Overexpression of EGFR has been associated with a poorer prognosis in patients with cancer, therefore its inhibition may lead to the suppression of tumor proliferation improving clinical outcome. Strategies to block EGFR include development of monoclonal antibodies to EGFR, tyrosine kinase inhibitors, ligand-linked toxins, and antisense approaches. This article will focus on cetuximab and other monoclonal antibodies and their applications in the treatment of advanced NSCLC.
Keywords: EGFR, monoclonal antibodies, NSCLC, cetuximab, panitumumab, matuzumab
Reviews on Recent Clinical Trials
Title: The Role of Cetuximab and Other Epidermal Growth Factor Receptor Monoclonal Antibodies in the Treatment of Advanced Non-Small Cell Lung Cancer
Volume: 3 Issue: 3
Author(s): Antonio Rossi, Emilio Bria, Paolo Maione, Giovanni Palazzolo, Marzia Falanga and Cesare Gridelli
Affiliation:
Keywords: EGFR, monoclonal antibodies, NSCLC, cetuximab, panitumumab, matuzumab
Abstract: Lung cancer continues to be the leading cause of cancer-related deaths in the western civilization and developing countries. Non-small cell lung cancer (NSCLC) accounts for > 85% of all cases of lung cancer. Since most patients with NSCLC have advanced disease at diagnosis, to date chemotherapy with third-generation platinum-based doublets represents the standard of care. However, a plateau has been reached with the use of cytotoxic chemotherapy in advanced NSCLC. Advances in the knowledge of tumour biology and mechanisms of oncogenesis have granted the singling out of several molecular targets for NSCLC treatment. In particular, the epidermal growth factor receptor (EGFR), a member of the ErbB family and commonly overexpressed in NSCLC, is one of the most studied targets. Overexpression of EGFR has been associated with a poorer prognosis in patients with cancer, therefore its inhibition may lead to the suppression of tumor proliferation improving clinical outcome. Strategies to block EGFR include development of monoclonal antibodies to EGFR, tyrosine kinase inhibitors, ligand-linked toxins, and antisense approaches. This article will focus on cetuximab and other monoclonal antibodies and their applications in the treatment of advanced NSCLC.
Export Options
About this article
Cite this article as:
Rossi Antonio, Bria Emilio, Maione Paolo, Palazzolo Giovanni, Falanga Marzia and Gridelli Cesare, The Role of Cetuximab and Other Epidermal Growth Factor Receptor Monoclonal Antibodies in the Treatment of Advanced Non-Small Cell Lung Cancer, Reviews on Recent Clinical Trials 2008; 3 (3) . https://dx.doi.org/10.2174/157488708785700276
DOI https://dx.doi.org/10.2174/157488708785700276 |
Print ISSN 1574-8871 |
Publisher Name Bentham Science Publisher |
Online ISSN 1876-1038 |
![](/images/wayfinder.jpg)
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Recent Advances in Optical Cancer Imaging of EGF Receptors
Current Medicinal Chemistry Strategies to Overcome or Circumvent P-Glycoprotein Mediated Multidrug Resistance
Current Medicinal Chemistry Role of Tyrosine Kinase Inhibitors in Lung Cancer
Anti-Cancer Agents in Medicinal Chemistry Glucose Oncometabolism of Esophageal Cancer
Anti-Cancer Agents in Medicinal Chemistry Overexpression of Nemo-like Kinase Promotes the Proliferation and Invasion of Lung Cancer Cells and Indicates Poor Prognosis
Current Cancer Drug Targets Isothiocyanates as Cancer Chemopreventive Agents: Their Biological Activities and Metabolism in Rodents and Humans
Current Drug Metabolism Cytotoxic and Antitumoral Activity of N-(9H-purin-6-yl) Benzamide Derivatives and Related Water-soluble Prodrugs
Current Molecular Pharmacology Synthesis and Anticancer Activities of New Benzothiadiazinyl Hydrazinecarboxamides and Anilino[1,2,4]triazolo[1,5-b][1,2,4]thiadiazine 5,5-diones
Medicinal Chemistry Lysosomal Modulatory Drugs for a Broad Strategy Against Protein Accumulation Disorders
Current Alzheimer Research Conditionally Replicating Adenoviruses for Cancer Treatment
Current Cancer Drug Targets NBS1 Heterozygosity and Cancer Risk
Current Genomics Discovery of Multi-target Anticancer Agents Based on HDAC Inhibitor MS-275 and 5-FU
Medicinal Chemistry Phenotyping of Cytochrome P450 2E1 In Vitro and In Vivo
Current Drug Metabolism Protein-protein Interactions: Network Analysis and Applications in Drug Discovery
Current Pharmaceutical Design Target Driven Preclinical Screening for New Antimitotic Chemotherapy Agents
Current Topics in Medicinal Chemistry Signal Transduction Therapy: Challenges to Clinical Trial Design
Current Signal Transduction Therapy Single-cell RNA Sequencing Analysis Identifies Key Genes in Brain Metastasis from Lung Adenocarcinoma
Current Gene Therapy Tetraspanins - Gateways for Infection
Infectious Disorders - Drug Targets Metal Containing Chloroquinolines: Beyond Hit and Miss Antimalarial Efficacy to Solid Science
Mini-Reviews in Medicinal Chemistry Electrochemical Indicators for DNA Electroanalysis
Current Analytical Chemistry